CLINICAL_TRIALS ClinicalTrials.gov record update

A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07907965
Title field or adapter rule: {'original_value': 'A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:34.194822+00:00
Published At: 2026-10-30T00:00:00+00:00
Record Updated At: 2026-10-30
Source Retrieved At: 2026-10-31T22:18:45.365006+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Diabetic Kidney Disease (DKD)", "Type 2 Diabetes", "Albuminuria"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07907965"
protocolSection.identificationModule.officialTitle: "A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Double-Dose Guominkang Group', 'Standard-Dose Guominkang Group'], 'description': 'Guominkang Granules is a traditional Chinese herbal formula composed of multiple herbs, used to regulate immune inflammation and metabolic dysfunction in patients with diabetic kidney disease. In this study, it is administered orally once daily at a dose of either 1 bag or 2 bags for 12 weeks.', 'name': 'Guominkang Granules', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Double-Dose Guominkang Group', 'Observation Group', 'Standard-Dose Guominkang Group'], 'description': '1. Antihypertensive therapy:\n\n Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), combined with calcium channel blockers (CCBs) and/or diuretics as clinically indicated.\n2. Antidiabetic agents:\n\n Metformin; sulfonylureas (e.g., glimepiride, gliclazide, glipizide, gliquidone); alpha-glucosidase inhibitors (e.g., acarbose, voglibose); thiazolidinediones (e.g., rosiglitazone, pioglitazone); glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., exenatide, liraglutide, lixisenatide); dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin, linagliptin, saxagliptin, alogliptin); and/or sodium-glucose cotransporter-2 (SGLT2) inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin).\n3. Lipid-lowering therapy:\n\nStatins (e.g., pravastatin, fluvastatin, simvastatin, atorvastatin); fibrates (e.g., fenofibrate, bezafibrate); and other lipid-modifying agents (e.g., acipimox, gemfibrozil, ezetimibe).', 'name': 'Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.